Hepaxane

Hepaxane is a prescription medication whose active ingredient is enoxaparin sodium, a low‑molecular‑weight heparin. It is supplied in an injectable form for subcutaneous, intravenous, or hemodialysis administration, although the exact strength and dosage form are not specified in the available product information. Hepaxane is marketed in the European Union and is classified as an antithrombotic agent used to reduce the risk of clot formation in clinical practice.

Hepaxane is indicated for several antithrombotic purposes where prevention or treatment of venous thromboembolism is required in hospitalized or ambulatory patients.

- Prevention of deep vein thrombosis (DVT) in patients undergoing surgery or immobilization. - Treatment of established DVT to reduce clot propagation and recurrence. - Prevention and treatment of pulmonary embolism (PE) in at‑risk individuals. - Anticoagulation during hemodialysis to maintain circuit patency. - Prophylaxis of clot formation in other clinical situations where thrombotic risk is elevated.

Like other low‑molecular‑weight heparins, Hepaxane may cause adverse reactions, most of which are mild and transient, while rare events can be serious.

Common: - Injection site bruising, pain, or erythema. - Minor gastrointestinal upset such as nausea or dyspepsia. - Transient elevation of liver enzymes. - Mild bleeding from gums, nose, or minor cuts.

Serious: - Significant hemorrhage, including internal or intracranial bleeding. - Thrombocytopenia, especially heparin‑induced thrombocytopenia (HIT).

Before initiating Hepaxane, clinicians should evaluate patient‑specific factors and monitor for conditions that could increase bleeding risk or affect drug safety throughout therapy.

- History of active bleeding, recent surgery, or trauma. - Severe renal impairment (creatinine clearance <30 mL/min) requiring dose adjustment. - Concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics. - Known hypersensitivity to enoxaparin, heparin, or any excipients. - Pregnancy and lactation status should be assessed, as safety data are limited. - Regular monitoring of platelet counts and anti‑Xa levels in high‑risk patients.

Hepaxane can interact with several medications, potentially altering anticoagulant effect or increasing bleeding risk; awareness of these interactions guides safe prescribing in clinical practice.

Avoid: - Concurrent use of other injectable anticoagulants (e.g., unfractionated heparin, fondaparinux) without specific monitoring. - Strong antiplatelet drugs such as clopidogrel or ticagrelor when high bleeding risk is present.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin, which may increase minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents. - Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulant effect. - High‑dose corticosteroids.